Pacira Pharmaceuticals recalls
FDA enforcement reports naming PACIRA PHARMACEUTICALS INC as the recalling firm.
- Recall reports
- 4
- Class I (serious)
- 0
- Most recent report
- Jul 3, 2024
- Jul 3, 2024Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per vi…Drug · PACIRA PHARMACEUTICALS INCFailed Dissolution Specifications - did not meet the acceptance criteria for IVR Level 3 testing at 9 months 2-8¿C followed by 6 weeks at 25¿CClass II
- Jun 19, 2024Drug Vial Label: Zilretta¿ (triamcinolone acetonide extended-release injectable suspens…Drug · PACIRA PHARMACEUTICALS INCFailed Stability Specifications - at 12 months 2-8 degrees C followed by 6 weeks at 25 degrees C.Class II
- Dec 11, 2019EXPAREL, Bupivicaine Liposome Injectable Suspension, 1Drug · Pacira Pharmaceuticals, Inc.Sub Potent Drug: Out of Specification (OOS)Class II
- Mar 6, 2013EXPAREL (bupivacaine liposome injectable suspension), 1Drug · Pacira Pharmaceuticals, Inc.Subpotent; bupivacaineClass II